{"id":608245,"date":"2022-07-15T18:08:01","date_gmt":"2022-07-15T18:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=608245"},"modified":"2022-07-15T18:08:01","modified_gmt":"2022-07-15T18:08:01","slug":"infectious-disease-diagnostics-market-worth-331-billion-by-2027-exclusive-report-by-marketsandmarkets","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/infectious-disease-diagnostics-market-worth-331-billion-by-2027-exclusive-report-by-marketsandmarkets_608245.html","title":{"rendered":"Infectious Disease Diagnostics Market worth $33.1 billion by 2027 – Exclusive Report by MarketsandMarkets\u2122"},"content":{"rendered":"
\n
\"Infectious<\/a><\/div>\n
\n
Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioM\u00e9rieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US) are some of the major key players<\/div>\n<\/div>\n<\/div>\n
In February 2021, Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.<\/div>\n

According to the new market research report “Infectious Disease Diagnostics Market<\/a> by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) – Global Forecast to 2027″,<\/strong> published by MarketsandMarkets™, the market is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.<\/p>\n

Browse in-depth TOC on <\/em>“Infectious Disease Diagnostics Market”<\/strong>
164 – Tables<\/strong>
51 – Figures<\/strong>
294 – Pages<\/strong><\/strong><\/p>\n

Download PDF Brochure: <\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=116764589<\/a><\/p>\n

The global prevalence of infectious diseases and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements are factors supporting the growth of this market. Growth opportunities in growing economies provide lucrative opportunities for the players operating in the infectious disease diagnostic market.<\/p>\n

The reagents, kits, and consumables segment accounted for the largest share of the infectious disease diagnostics market, by product & service segment, in 2021<\/strong><\/p>\n

Based on product & service, the infectious disease diagnostic market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2021, the reagents, kits, and consumables segment accounted for the largest share of this market. The requirement of reagents, kits, and consumables in large numbers compared to instruments is the main factor contributing to the large share of this segment. Unlike instruments, reagents, kits, and consumables segment requires repeat purchases, which results in its stable demand among end users.<\/p>\n

POC testing segment to register the highest CAGR during the forecast period<\/strong><\/p>\n

Based on the type of testing, the infectious disease diagnostics market has been segmented into laboratory testing and POC testing. In 2021, the POC testing segment accounted for the highest CAGR. This can be attributed to the need to closely monitor patient conditions and advantages such as faster diagnosis.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=116764589<\/a><\/p>\n

The COVID-19 segment accounted for the largest share of the infectious disease diagnostics market, by disease type segment, in 2021<\/strong><\/p>\n

Based on disease type, the market is segmented into COVID-19, HIV, HAIs, hepatitis, CT, NG, HPV, Tuberculosis, influenza, syphilis, mosquito-borne diseases and other infectious diseases. In 2021, the COVID-19 disease type segment accounted for the largest share of this market due to factors such as the increasing number of cases and the availability of many COVID-19 diagnostic tests.<\/p>\n

The diagnostic laboratories segment accounted for the largest share of the infectious disease diagnostics market, by end user segment, in 2021<\/strong><\/p>\n

Based on end user, the infectious disease diagnostic market has been segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. In 2021, diagnostic laboratories accounted for the largest share of the market. Diagnostic laboratories command the major share of the market owing to increased test volume of infectious diseases and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.<\/p>\n

Speak to Analyst: <\/strong>https:\/\/www.marketsandmarkets.com\/speaktoanalystNew.asp?id=116764589<\/a><\/p>\n

North America is the largest regional market for infectious disease diagnostics market<\/strong><\/p>\n

The infectious disease diagnostic market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the market. The large share of this region can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.<\/p>\n

The major players operating in this infectious disease diagnostics market are  Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/infectious-disease-diagnostics-market-116764589.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioM\u00e9rieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US) are some of the major key players In February 2021, Thermo Fisher Scientific acquired Mesa Biotech (US) … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-608245","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/608245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=608245"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/608245\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=608245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=608245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=608245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}